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by LDL-C but treated to both LDL-C and LPL-P recommended goals. Results: In 
the general population, the costs per quality-adjusted life year (QALY) associated 
with the use of LDL-P alone were $76,052 at 5 years and $8,913 at 20 years and 
with the use of both markers were $142,825 at 5 years and $25,505 at 20 years. 
In high-risk subpopulations, the use of LDL-P alone was cost-saving at 5 years; 
whereas the cost per QALY for the use of both markers was $14,250 at 5 years and 
$859 at 20 years for high-risk dyslipidemics, $19,192 at 5 years and $649 at 20 years 
for diabetics, and $9,030 at 5 years and $7,268 at 20 years for patients with prior 
CHD. ConClusions: Utilizing LDL-P to guide statin therapy is cost-effective in 
the long term for the general population, and cost-saving or cost-effective in the 
short term for high-risk patients.
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objeCtives: The aim of this study was to evaluate the long-term cost effectiveness 
of ticagrelor + aspirin versus clopidogrel + aspirin in patients with acute coronary 
syndrome (ACS) treated for 12 months in Spain. Methods: The cost effective-
ness model consisted of a decision tree (1st year) based on the PLATO study and 
a long-term Markov model (2nd year onwards). This allowed estimation of cardio-
vascular events (death, myocardial infarction and non-fatal stroke), survival, health 
costs, and health related quality of life. A life time horizon was applied. The daily 
drug cost was € 0.60 and € 2.96 for generic clopidogrel and ticagrelor, respectively. 
Spanish unit costs and life tables were used; outcomes and costs were discounted 
at 3%. A sensitivity analysis across subgroups was carried out, and probabilistic 
sensitivity analysis was used to validate the robustness of the model. Results: 
Ticagrelor compared to clopidogrel was associated with a gain of 0.1586 life years 
and 0.1363 years of quality-adjusted life years (QALY), with an incremental cost of € 
596. The incremental cost per life year and per QALY gained was € 3,760 and € 4,374, 
respectively. The probabilistic sensitivity analysis showed that ticagrelor was cost-
effective versus clopidogrel in > 99 % of the simulations given a willingness-to-pay 
threshold of € 15,000/QALY. The results were consistent across different subgroups 
of ACS patients. ConClusions: Ticagrelor + aspirin for 12 months is a cost effective 
treatment compared to generic clopidogrel + aspirin in patients with ACS treated 
invasively or conservatively, based on the findings of the PLATO study and Spanish 
health care costs.
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objeCtives: This study was conducted to determine the cost-effectiveness of 
carotid Artery stenting (CAS) versus carotid endarterectomy (CEA) in patients with 
symptomatic carotid stenosis (more than 50% stenosis) in Korean health care sys-
tem perspective. Methods: We performed a cost-utility analysis. Costs were esti-
mated from retrospective chart review (CAS= 346, CEA= 331), health insurance claims 
data, and other national resources and expressed in 2013 KRW. Transition probabili-
ties were estimated from retrospective chart and systematic review. Health utility 
index was assessed for general population using Time Trade Off (TTO) with health 
scenario. We used a Markov model to project 15-year costs and quality-adjusted 
life years (QALYs) for the 2 treatment groups. Results: In the base case analysis, 
CAS produced 6.49 QALYs, compared with 6.71 QALYs for CEA. The incremental 
cost of stenting was 1,691,740 KRW. In the base case analysis, CEA for patients 
with symptomatic stenosis had a greater benefit than CAS, with lower costs. In 
subgroup for patients with stenosis more than 70% or patient with over 80 years 
old, CAS was cost-effective. Sensitivity analyses showed that the major stroke or 
mortality influenced the results. However the results were consistent with the base 
analysis. ConClusions: Under the current circumstances in Korea, CEA was domi-
nated by CEA in symptomatic steonsis. Therefore we concluded that CEA would be 
cost-effective intervention for carotid stenosis. To be economically competitive, the 
clinical effectiveness such as mortality and major stroke rates of CAS must be at 
least equivalent if not less than those of CEA.
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objeCtives: To estimate productivity loss and associated indirect costs in working-
age patients treated for hyperlipidemia. Methods: A retrospective population-
based cohort study was conducted using Swedish electronic medical records 
linked to national health registers and the Social Insurance Register. Patients were 
included based on a prescription of lipid-lowering therapy between January 1,2006 
and December 31,2011 and followed until December 31,2012 for estimation of pro-
ductivity loss and cost outcomes. Patients were stratified into three cohorts based 
on cardiovascular (CV) risk level. Results: Total mean days lost, measured as the 
sum of net sick leave and net disability pension days, during the one-year period 
following study inclusion was highest in the CV event history cohort (n= 6,881; 159 
days), followed by the CV risk equivalent (RE) cohort (n= 3,226; 131 days) and the low/
cost savings at 3 years is estimated to be 11.671€ per patient. ConClusions: The 
use of the GORE® PROPATEN® Vascular Graft for infrapopliteal bypass in the PAD 
patient population represents a safe, clinically effective, and cost-saving alternative 
to standard ePTFE vascular grafts.
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objeCtives: Pharmacoeconomic analysis of rosuvastatin use in patients with 
hypercholesterolemia in the health care of Belarus has been performed to deter-
mine economic advisability of its applying in Belarus. As there is own production 
of statins (generics of lovastatin, atorvastatin and simvastatin) in Belarus, the 
insclusion of new statin (rosuvastatin) in the clinical protocols requires pharma-
coeconomic study. Methods: Overview of statins available in Belarus has been 
conducted. Equivalent effective dose to achieve target of low density lipoprotein 
cholesterol (CH-LPLD) values were established on the basis of published data. Cost-
minimization analysis has been used. Model “decision tree” to achieve the target 
CH-LPLD values has been built on the basis of STELLAR trial. Statin doses required 
to achieve the target CH-LPLD values have been calculated. The costs of achieving 
the target CH-LPLD values have been evaluated. The cost of each statins treating 
during the year has been calculated. Results: The highest cost has been obtained 
for the equivalent dose of lovastatin ($ 0.35) compared with atorvastatin ($ 0.31) and 
simvastatin ($ 0.28) manufactured in Belarus. Average price rosuvastatin (Merten 
®) was comparable to the cost ($ 0.21) of Belarusian generics. The average cost of 
achieving the target CH-LPLD level was the lowest in the case of rosuvastatin - $ 170 
compared with atorvastatin ($ 200) and simvastatin ($ 286) considering available 
statins of all manufacturers. Due to rosuvastatin’s lower effective dosage the costs 
of the one-year treatment with rosuvastatin is lower (on average 94 $) than with 
atorvastatin (all manufacturers - $ 100) and simvastatin (202 $). ConClusions: 
The study has demonstrated pharmacoeconomic acceptability of rosuvastatin use 
in the health care of Belarus.
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objeCtives: To assess cost-effectiveness of indapamide 1.5 mg +amlodipine 5/10 
mg single-pill combination (SPC) compared with free combination (FC), in the 
Polish setting. Methods: A Markov cohort simulation model was used. Results 
of meta-analysis by Gupta et al show a difference in patients’ compliance between 
SPC and FC. Better compliance results in lower systolic blood pressure, which 
influences risk of cardiovascular events. Hence, compliance is associated with 
life expectancy and quality of life. Cardiovascular disease risks were based on 
the Framingham risk equations. Life-time horizon, Polish public payer perspec-
tive and patient perspective were applied. Indapamide/amlodipine SPC cost is 
based on average pharmacy prices reported in April 2014 (18.13PLN and 19.75PLN 
respectively for 1.5+5mg and 1.5+10mg /30 tabs); 30% patient copayment was 
assumed. Cost of FC was calculated as an average cost of reimbursed indapamide 
and amlodipine products in corresponding doses. All costs present 2014 values, 
and are expressed in Polish zloty (PLN). Costs and effects were discounted with 
5% and 3.5% rates. Results: Indapamide/amlodipine SPC compared with FC gen-
erates additional life years (LYs) and quality adjusted life years (QALYs), and is 
highly cost-effective from public payer perspective and dominant from patient 
perspective. Difference between SPC and FC in LYs and QALYs was: 0.007960 and 
0.020809. Difference in total costs from public payer perspective and from patient 
perspective was 113.14PLN (27.07EUR) and -211.31PLN (-50.56 EUR). ICUR from 
public payer perspective was 5,437PLN/QALY (1,301EUR/QALY). At prices +199% vs 
the base-case, SPC remains a cost-effective technology from public payer perspec-
tive according to the legally defined CE threshold (111,381PLN/QALY= 26,653EUR/
QALY). At prices -9.9% vs base-case, SPC is a dominant/cost saving technology vs 
the FC comparator. ConClusions: From public payer perspective, indapamide/
amlodipine SPC compared with FC is a highly cost-effective treatment option for 
hypertensive patients in contemporary Polish setting. From patient perspective, 
SPC is a dominant technology.
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objeCtives: Numerous trials have shown that lowering LDL cholesterol (LDL-C) 
reduces CVD events; however, at any LDL-C level, residual risk remains. LDL parti-
cle concentration (LDL-P) may be a better predictor of events, but no studies have 
evaluated its cost-effectiveness. We used the Archimedes model to evaluate the 
cost-effectiveness of using LDL-C or LDL-P in preventing cardiovascular disease 
in dyslipidemic patients. Methods: Archimedes is a highly detailed, large-scale 
simulation model of physiology, disease and health care systems. We created a 
simulated population of 1,000,000 individuals age 20-84 reflective of real subjects 
in the NHANES dataset. Because NHANES does not contain LDL-P values, they 
were imputed maintaining covariance with other biomarkers. The study had three 
arms: •Control: subjects evaluated for therapy for elevated LDL-C and treated 
with statins to LDL-C goals outlined in ATP-III; •LDL-P Alone: subjects evaluated 
and treated based solely on their LDL-P values; •Dual Arm: subjects evaluated 
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objeCtives: The objective of the project is to evaluate the impact of health care 
resources and the related health care costs in relation to outcomes occurred in 10 
years on the cohort of 2002 and intervention on secondary prevention cohort 2010 
with a follow-up to 3 years. Methods: In 2002, Local HealthCare Unit (ASLn°1) 
of Milan identified a cohort of 33,977 patients with RCV (Cardiovascular risk). 
Data analysis was done trough a retrospective claims data study from ASLn°1 
of Milan; Physicians who participated were 494. Information has been collected 
for inclusion in the study regarding some risk factors and treatment. At the end 
of 2010, all recruited patients were started on a program of secondary preven-
tion, by reducing the effects of smoking and BMI after ad hoc training events 
for physicians. Results: 12,000 subjects were recruited and followed for 3 years 
with reduction of spending on the NHS system and reduced incidence of events. 
A resources utilization analysis has been developed using profiles of treatments 
and dividing the population into groups with homogeneous treatment (smoking 
and BMI control vs. standard care), verifying the occurrence of greater outcomes 
and related health care costs. Data are analyzed with the definition of major car-
diovascular events, all-cause mortality and cause-specific, occurrence of diabetes 
and other chronic greater diseases, verifying the occurrence of greater outcomes 
and related health care costs. ConClusions: Administrative databases offer 
low-cost information (since they are already available) regarding more or less all 
services provided in a health care environment. These sources and their integra-
tion are a powerful tool supporting conventional methods used in epidemiological 
studies and as tools for plan Health care policy.
CArdioVAsCulAr disordErs – Patient-reported outcomes & Patient Prefer-
ence studies
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objeCtives: To examine the relationship between medication compliance, cardio-
vascular risk and gender in hypertensive patients visiting primary health care cent-
ers. Methods: A prospective 1-year study was conducted in rural communes in 
Vietnam on hypertension management in a population from 35 to 64 years. Data on 
age, gender, blood pressure and blood test were collected at baseline. Cardiovascular 
risk was based on the Cardiovascular Risk Prediction Model for populations in 
Asia. Medication compliance was calculated as the number of days taking the drug 
divided by the number of days since the first day of the prescription. A threshold of 
80% was applied to differentiate between compliance or non-compliance. Taking 
medication was based on patients’ self-report during each monthly visit. Results: 
Of total 338 patients met the selection criteria for medication compliance study, 
46% was female. Mean age was 53.5 (+/- 6.9) and 77.2 % of patients was < 10% of 
CVD risk in 8 years. In primary health care settings, medication compliance was 
49%. No significant difference in medication compliance in both CVD risk groups 
(< 10% vs. > 10% risk) was found, also not after controlling for age and gender 
(adjusted OR was 1.27; 95 % CI: 0.7 – 2.2; p value 0.39). The odds of medication com-
pliance in females was however 0.6 times higher than in males (95% CI: 0.38 to 0.95, 
p value 0.028). Each 1 year increase, results in patients being 1.04 times more likely 
to be compliant (95% CI: 1.009 to 1.076, p value 0.01). ConClusions: Medication 
compliance rate was low among hypertensive patients in Vietnam. CVD risk at the 
baseline did not significantly differentiate complaint from non-compliant patients. 
Yet, a major difference in compliance was found for gender. Rather than risk profile, 
gender should be considered for guiding the choice on who to target for improving 
medication compliance for hypertensive patients.
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objeCtives: To explore the associations of selected health behaviors with medica-
tion adherence in elderly patients aged 65+ years with hypertension, diabetes, or 
hyperlipidemia. Methods: The Korean National Health Insurance data between 
January 2010 and June 2011 were used. The study included 662,170 hypertensive, 
179,285 diabetic, and 244,702 hyperlipidemic patients. Poor medication adher-
ence was defined as < 80% medication possession ratio from January to June 2011. 
Health behavior data were from year 2010. Multivariate logistic regression was 
used. Results: Patients with a waist circumference < 85 (for women) or 90 (for 
men) centimeters were more likely to adhere to their medications. Current smok-
ers and moderate or heavy drinkers showed poor medication adherence than their 
counterparts. Mild physical activity was associated with better medication adher-
ence. ConClusions: Public efforts need to focus on improving comprehensive 
control of both health behaviors and medication adherence.
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objeCtives: More than half of people who have experienced a myocardial infarc-
tion (MI) are not adherent to their medication regimen, which leads to poorer health 
outcomes. We used a stated-preference (SP) study to examine factors that could 
influence patient compliance to prophylactic cardiovascular treatments, and discuss 
practical issues in using SP methods to explain medication adherence. Methods: 
Preference data for treatments that lower the risk of cardiovascular events were 
collected from 464 respondents in the United States with self-reported history of MI 
using a discrete-choice experiment (DCE). All respondents answered 11 judgment 
unknown risk cohort (n= 2,497; 86 days). The annual indirect cost related to work 
productivity loss was estimated at 209,704 SEK for treated hyperlipidemia patients 
with CV event history. Corresponding data for CV RE patients and patients at low/
unknown risk were 168,517 SEK and 108,429 SEK, respectively. The higher CV risk 
levels were associated with greater productivity losses. Indirect costs varied within 
cohorts depending on past diagnoses of the patients. In patients with CV event his-
tory, a previous diagnosis of myocardial infarction was associated with the lowest 
annual indirect costs (189,114 SEK) while a past diagnosis of ischemic stroke was 
associated with the highest indirect costs (281,985 SEK). Within the CV RE cohort, a 
previous diagnosis of abdominal aortic aneurysm and transient ischemic attack was 
associated with the highest (264,441 SEK) and lowest annual indirect costs (156,254 
SEK), respectively. ConClusions: The high level of productivity losses illustrates 
the high indirect cost burden in patients treated for hyperlipidemia. The type of 
past CV event affected the level of indirect costs.
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objeCtives: To estimate annual incremental health care costs of new cardiovascu-
lar (CV) events (myocardial infarction, unstable angina, revascularization, ischemic 
stroke, transient ischemic attack or heart failure) in patients with hyperlipidemia 
or prior CV events. Methods: A retrospective population-based cohort study was 
conducted using Swedish electronic medical records and national registers. Patients 
were included in the study based on a prescription of lipid-lowering treatment 
between January 1, 2006 and December 31, 2006 or history of CV events (prior to 
2006) and followed until December 31, 2012 for identification of new CV events and 
estimation of cost. Patients were stratified into three cohorts based on CV risk level. 
Propensity score matching was applied to compare patients with new events to 
patients without new events and to estimate incremental costs. Results: A new 
CV event resulted in increased costs during all follow-up years. Inpatient hospital 
stays were the main driver of the increase. The majority of the costs occurred in 
the first year following event when patients with CV event history (n= 6,881) had 
an incremental cost of 74,758 SEK. This was similar to that of CV risk-equivalent 
patients (n= 3,226; 75,415 SEK) and patients at low/unknown CV risk (n= 2,497; 72,635 
SEK). Ischemic stroke resulted in the highest first year cost in all cohorts (88,739; 
85,516; and 87,668 SEK) and transient ischemic attack the lowest (34,098; 36,042; 
and 29,052 SEK). Incremental costs during subsequent years remained elevated for 
all cohorts, with the CV event history cohort having the highest costs. Second year 
incremental costs varied between 10,689 and 15,082 SEK and third year costs varied 
between 8,828 and 11,558 SEK across cohorts. ConClusions: The direct costs of 
new CV events were substantial and varied considerably by type of event. Costs were 
increased during all follow-up years, regardless of CV risk level.
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objeCtives: As part of a non-interventional study, hospitalizations due to the 
following diagnoses of cardiovascular disease (CVD) were documented: atrial fibril-
lation (AF), stroke or TIA (SoT), acute coronary syndrome (ACS), arterial embo-
lism (AE), decompensated heart failure (DHF), syncope (S), ventricular arrhythmia 
(VA), and cardiac arrest (CA). The objective of this cost analysis was to quantify 
inpatient treatment costs for each diagnosis in Germany from the perspective of 
the statutory health insurance. Methods: The analysis was conducted for 2012 
using the latest available “G-DRG V2013 Browser 2012 § 21 KHEntgG”. Invoiced 
diagnosis-related groups (DRGs) including the ICD10-codes corresponding to the 
considered diagnoses were collected. For available DRGs, the number of cases with 
normal length of stay and the corresponding cost weights (CWs) were documented. 
Then, the proportion of an individual DRG within a diagnosis (≥ 1 ICD10-code) 
was calculated (number of cases for individual DRG / sum of all cases for every 
DRG within a diagnosis = “DRG weight factor”). Next, the CWs of an individual 
DRG were multiplied by the “DRG weight factor” to reflect the prevalence of a DRG 
within an ICD10-code (“weighted CWs”). Finally, the “weighted CWs” were added 
up to obtain an average CW for a diagnosis, which is based on all DRGs and CWs 
coded for this single diagnosis. This sum of CWs was multiplied by the state-wide 
base rate of 2,991.53€ . Results: The following inpatient treatment costs for the 
respective diagnoses were derived: 2,800€ (AF); 5,000€ (SoT); 5,200€ (ACS); 6,200€ 
(AE); 3,800€ (DHF); 1,900€ (S); 8,200€ (VA); 15,900€ (CA) (rounded). ConClusions: 
Inpatient treatment costs for the considered CVD diagnoses vary from 1,900€ to 
15,900€ . Generally, hospitalizations due to CVD have a remarkable impact on the 
budget of German sick funds. The results of this cost study can be used for further 
health economic analyses in CVD.
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